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Abstract
 .Recombinant rat macrophage inflammatory protein 2 MIP-2 was prepared from E. coli transfected with a glutathione-
 .S-transferase GST -MIP-2 fusion protein expression vector. A polyclonal antibody to rat MIP-2 was then obtained from
rabbits by immunization with recombinant rat MIP-2. Using the polyclonal antibody which selectively suppressed
neutrophil chemotactic activity of MIP-2, the role of MIP-2 in neutrophil infiltration in allergic inflammation in rats was
studied. In an air pouch-type allergic inflammation model in rats, neutrophil infiltration into the pouch fluid increased with
time after antigen challenge. Neutrophil chemotactic activity in the pouch fluid collected 8 h after antigen challenge was
diminished by anti-MIP-2 antibody. In addition, when leukocytes that had infiltrated into the pouch fluid collected 4 h after
antigen challenge were incubated, neutrophil chemotactic activity in the conditioned medium increased time-dependently,
and the activity was neutralized by anti-MIP-2 antibody. Furthermore, when anti-MIP-2 antibody was injected into the
pouch 6 h after antigen challenge, neutrophil infiltration into the pouch fluid during the next 2 h was suppressed. These
findings indicate that MIP-2 plays an important role in neutrophil infiltration in rat allergic inflammation. q 1997 Elsevier
Science B.V.
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1. Introduction
Migration of neutrophils into sites of inflammation
is induced by chemoattractants such as activated
 . w xcomplement components C5a and C3a 1 ,
 . w xleukotriene LT B 2,3 , platelet-activating factor4
 . w x  .PAF 4 and chemokines including interleukin IL
) Corresponding author. Fax: q81 22 2176859
w x w x8 5,6 in humans 7 . In rats, chemokines are classi-
fied into cytokine-induced neutrophil chemoattractant
 .CINC -1, CINC-2 a , CINC-2 b , and macrophage
inflammatory protein 2 MIP-2, also known as CINC-
. w x3 8 . In an air pouch-type allergic inflammation
w xmodel in rats 9 , we demonstrated previously that the
neutrophil chemotactic activity in the pouch fluid
w xincreases from 2 to 8 h after antigen challenge 10 .
Furthermore, we found that leukocytes collected from
the pouch fluid 4 h after antigen challenge produce
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two neutrophil chemotactic factors named leukocyte-
 .derived neutrophil chemotactic factor LDNCF -1
 . minor component and LDNCF-2 major compo-
. w xnent 11,12 . Determination of partial amino acid
sequences of purified LDNCF-2 revealed that this
w xfactor is identical to rat MIP-2 10 . The production
of MIP-2 by the infiltrating leukocytes was suggested
by the finding that the level of MIP-2 mRNA in the
leukocytes at 4 h increased time-dependently in cul-
w xture 10 .
MIP-2 was purified as a potent chemoattractant
from the conditioned medium of lipopolysaccharide-
 .stimulated murine macrophages RAW 264.7 by
w xWolpe et al. 13 . Recently, it has been reported that
MIP-2 increases expression of adhesion molecules
and evokes a slight respiratory burst in neutrophils
w x14 . Production of MIP-2 in inflammatory loci has
been suggested in several experimental models in
animals, including LPS-induced lung injury in rats
w x15 , and experimental listeria meningoencephalitis
w xin mice 16 . In addition, anti-MIP-2 antibody sup-
w xpressed glomerulonephritis in rats 17 . These reports
suggested that MIP-2 plays a significant role in sev-
eral inflammation models. However, as yet no direct
evidence that MIP-2 acts as a neutrophil chemo-
attractant in allergic inflammation has been reported.
In the present study, we prepared recombinant rat
MIP-2 and obtained a polyclonal anti-MIP-2 anti-
body. Using this anti-MIP-2 antibody, we examined
the roles of MIP-2 in neutrophil infiltration in an air
pouch-type allergic inflammation model in rats.
2. Materials and methods
2.1. Cloning and expression of rat MIP-2
Total RNA was prepared from the leukocytes 2=
7 .10 cells which had infiltrated into the pouch fluid
collected 4 h after antigen challenge in an air pouch-
type allergic inflammation model in rats as described
below. The first-strand cDNA was synthesized from
the total RNA by M-MuLV reverse transcriptase
 .Gibco BRL, Gaithersburg, MD., USA , and used for
 XPCR amplification with primers for rat MIP-2 5 -
GCCTAGCGCCATGGCCCCTCCCACT-3X and 5X-
X .GGCACATCAGGTACGATCCAGGCTT-3 . The
resulting 413-base pair fragment of proMIP-2 was
 .cloned into pGEM-4T Promega, Madison, WI, USA .
DNA encoding the mature MIP-2 protein was ampli-
fied by PCR using the following primers containing
 X.  X.Bam HI 5 and Eco RI 3 restriction enzyme sites:
5X-GGATCCAGTGAGCTGCGCTGTCAA-3X and
5X-GAATTCTCAGTTAGCCTTGCCTTT-3X. The
PCR product was ligated into pGEX-4T-1 vector
 .Stratagene, La Jolla, CA, USA and transformed into
 .Escherichia coli strain BL 21 Stratagene for expres-
sion of GST-MIP-2 fusion protein. The construct was
verified by sequencing using a DyeDeoxye Termina-
tor Cycle Sequencing Core Kit Perkin Elmer, Ap-
.plied Biosystems Division, Foster City, CA, USA .
GST-MIP-2 was purified using a Glutathione
Sepharose 4B column Pharmacia Biotech, Uppsala,
.Sweden according to the manufacturer’s protocol.
Expression of GST-MIP-2 was confirmed by 15%
SDS-PAGE. To remove the GST portion of GST-
MIP-2, GST-MIP-2 was treated with 50 Urml
thrombin for 16 h at room temperature, yielding
GlySer-MIP-2.
2.2. Production of polyclonal antibody to MIP-2
New Zealand White rabbits were injected subcuta-
neously with 0.3 mg GST-MIP-2 emulsified in com-
plete Freund’s adjuvant FCA, Difco Laboratories,
.Detroit, MI, USA . Booster injections were given 11
times using 0.1 mg GST-MIP-2 in incomplete Fre-
 .und’s adjuvant Difco Laboratories at an interval of
10 days. Blood was withdrawn 7 days after the last
booster injection, and the IgG fraction was obtained
using a protein G column HiTrape, Pharmacia
.  .Biotech . Purified IgG anti-MIP-2 antibody was
used for the following experiments.
2.3. Induction of allergic inflammation
Immunization and induction of air pouch-type al-
lergic inflammation in rats were performed as de-
w xscribed previously 9 with slight modifications. An
antigen, azobenzenearsonate-conjugated acetyl bovine
 .serum albumin ABA-AcBSA , was prepared accord-
ing to the procedure described by Tabachnick and
w xSobotka 18 . Male rats of the Sprague-Dawley strain,
specific pathogen-free, weighing 120–140 g Charles
.River Japan, Kanagawa, Japan were immunized by
intradermal injection of 5 mg of the antigen as an
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emulsion with FCA. Nine days later, 8 ml of air was
injected subcutaneously on the dorsum to make an
ellipsoid-shaped air pouch. 24 h after injection of air,
2 mg of the antigen dissolved in 4 ml of a sterilized
 .solution of 0.8% wrv sodium carboxymethylcellu-
lose Cellogen F-3H; Daiichi Kogyo Seiyaku, Ni-
.igata, Japan in saline supplemented with 0.1 mgrml
penicillin G potassium, 0.1 mgrml streptomycin sul-
 .fate Meiji Seika Co., Tokyo, Japan and 52 mgrml
polymyxin B sulfate Sigma Chemical Co., St. Louis,
.MO, USA was injected into the air pouch to provoke
allergic inflammation. Non-immunized rats were in-
jected intradermally with FCA-emulsion without the
antigen and challenged in the same way as controls.
2.4. Preparation of the pouch fluid
The rats were sacrificed by cutting the carotid
artery under diethylether anesthesia, and the entire
pouch fluid was collected at the indicated times after
injection of the antigen solution into the air pouch.
The pouch fluid was centrifuged at 1500=g and 48C
for 10 min and the supernatant was diluted to 8-fold
with RPMI 1640 medium Nissui Seiyaku, Tokyo,
.  . Japan containing 0.25% wrv BSA BSA, essen-
.tially fatty acid-free; Sigma Chemical Co. for deter-
mination of neutrophil chemotactic activity.
2.5. Collection and culture of leukocytes
Leukocytes in the pouch fluid collected 4 h after
antigen challenge were obtained by centrifugation
 .350=g for 5 min at 48C and washed with phos-
 .phate-buffered saline pH 7.4 . The cells were sus-
pended in RPMI 1640 medium containing 0.25%
 . 7wrv BSA at a concentration of 1=10 cellsrml
and incubated at 378C for 4 h in 5% CO –95% air.2
After incubation, the suspension was centrifuged at
1,500=g and 48C for 10 min. The supernatant frac-
tion was obtained, diluted to 10-fold with RPMI 1640
 .medium containing 0.25% wrv BSA, and used for
the measurement of neutrophil chemotactic activity.
2.6. Measurement of neutrophil chemotactic acti˝ity
Neutrophil chemotactic activity of samples was
assayed using modified Boyden chambers as de-
w xscribed previously 4 . The migration rate was calcu-
 . lated as follows: migration rate % s number of
neutrophils in the lower chamberrnumber of neu-
.trophils applied in the upper chamber =100. As a
positive control, 12.5 nM CINC-1 Peptide Institute,
.Inc., Osaka, Japan in RPMI 1640 medium contain-
 .ing 0.25% wrv BSA was used. The migration
index for each sample was obtained from the follow-
 . ing equation: migration index % s migration rate
.for each samplermigration rate for 12.5 nM CINC-1
=100. Recombinant MIP-2 Pepro Tech, Rocky Hill,
.NJ, USA was used for comparison of neutrophil
chemotactic activity with GlySer-MIP-2.
2.7. Neutralization by anti-MIP-2 antibody of
chemotactic acti˝ity of samples
Each sample was preincubated with the indicated
concentrations of anti-MIP-2 antibody at 378C for 30
min, and remaining chemotactic activity was deter-
mined as described above.
2.8. Analysis of the in ˝i˝o effects of anti-MIP-2
antibody
 .Anti-MIP-2 antibody 1.6 mg dissolved in 1 ml of
saline was injected into the air pouch 6 h after
antigen challenge. Rats were then sacrificed 2 h later,
and the number of leukocytes in the pouch fluid was
counted using a hemocytometer. Aliquots of the cell
suspensions were smeared on glass slides, stained
with hematoxylin and eosin, and differential counting
of each type of cells was performed. Control rats
received 1 ml of saline containing 1.6 mg IgG ob-
tained from non-immunized rabbits.
2.9. Statistical analysis
The results are presented as means"S.E.M. Com-
parisons were performed with Student’s unpaired t-
test.
3. Results
3.1. Cloning and expression of rat MIP-2, and its
neutrophil chemotactic acti˝ity
Rat MIP-2 cDNA was cloned from infiltrated
 .leukocytes by reverse transcription RT -PCR. Re-
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Fig. 1. SDS-PAGE analysis of the expression and purification of GST-MIP-2. Lane 1, broad range molecular standard; lane 2,
pGEX-4T-MIP-2 transformant before IPTG induction; lane 3, pGEX-4T-MIP-2 transformant after IPTG induction; lane 4, supernatant of
cell lysate. Lane 5, flow through; lanes 6–8, washing; lanes 9–11, eluent obtained by Glutathione Sepharose 4B column chromatography.
combinant MIP-2 was expressed as a fusion protein
with GST in E. coli BL 21. Purified GST-MIP-2
migrated as a single band at about 35 kDa on SDS-
 .PAGE Fig. 1 . GST-MIP-2 did not show neutrophil
chemotactic activity at concentrations up to 50 nM.
Therefore, GST-MIP-2 was digested with thrombin to
Fig. 2. Chemotactic activity of GlySer-MIP-2 and MIP-2. GST-
 .MIP-2 was digested with thrombin, yielding GlySer-MIP-2 A .
The chemotactic activity of various concentrations of GlySer-
 .  .MIP-2 black bars and MIP-2 hatched bars in RPMI 1640
 .medium containing 0.25% wrv BSA was determined using
 .modified Boyden chambers B . The migration index is expressed
 .as a percentage of chemotaxis toward CINC-1 12.5 nM . Values
are the means"SEM of 4 determinations.
 .yield GlySer-MIP-2 Fig. 2A . Determination of neu-
trophil chemotactic activity of GlySer-MIP-2 re-
vealed that it has almost the same activity as that of
MIP-2, with maximal activity being at 3 to 10 nM
 .Fig. 2B .
3.2. Preparation of polyclonal antibody to MIP-2 and
its specificity
IgG was purified from sera of immunized rabbits,
and its specificity for MIP-2 was examined. GlySer-
MIP-2 and CINC-1 each at 5 nM, at which concentra-
tion maximum chemotactic activity for neutrophils
was observed, were preincubated with various con-
centrations of the anti-MIP-2 antibody or control IgG
from non-immunized rabbits, and neutrophil chemo-
tactic activity was than determined. As shown in Fig.
3, the chemotactic activity of GlySer-MIP-2 was
significantly inhibited by anti-MIP-2 antibody at 5
mgrml and was completely abolished at 10 mgrml.
IgG from non-immunized rabbits at concentrations up
to 30 mgrml showed no effect on neutrophil chemo-
tactic activity of GlySer-MIP-2.
To demonstrate the specificity of the anti-MIP-2
antibody, its effects on the neutrophil chemotactic
activity of CINC-1 were examined by the same ex-
perimental procedure. The neutrophil chemotactic ac-
tivity of CINC-1 was almost equivalent to that of
 .MIP-2 Fig. 2B . As shown in Fig. 4, anti-MIP-2
antibody at a concentration of 10 mgrml had no
influence on chemotactic activity of CINC-1 at 5 nM,
while neutrophil chemotactic activity by GlySer-
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Fig. 3. Effects of anti-MIP-2 antibody on the chemotactic activity
 .of GlySer-MIP-2. GlySer-MIP-2 5 nM in RPMI 1640 medium
 .containing 0.25% wrv BSA was preincubated with the indi-
 .cated concentrations of non-immunized rabbit IgG hatched bars
 .or anti-MIP-2 antibody black bars at 378C for 30 min. The
chemotactic activity was then determined using modified Boyden
chambers. The migration index is expressed as a percentage of
 .chemotaxis toward CINC-1 12.5 nM . Values are the means"
SEM of 4 determinations. Statistical significance: ))) P -0.001
vs. corresponding control.
 .MIP-2 5 nM was almost completely inhibited at this
concentration.
Furthermore, anti-MIP-2 antibody did not inhibit
the neutrophil chemotactic activities of 10 nM fMLP
 .or LTB data not shown .4
Fig. 4. Effects of anti-MIP-2 on the chemotactic activity of
 .  .CINC-1. CINC-1 5 nM or GlySer-MIP-2 5 nM in RPMI 1640
 .medium containing 0.25% wrv BSA was preincubated with
 .anti-MIP-2 antibody 10 mgrml at 378C for 30 min. The
chemotactic activity was then determined using modified Boyden
chambers. The migration index is expressed as a percentage of
 .chemotaxis toward CINC-1 12.5 nM . Values are the means"
SEM of 4 determinations. Statistical significance: ))) P -0.001
vs. corresponding control.
3.3. Neutrophil chemotactic acti˝ity in the pouch
fluid and its suppression by anti-MIP-2
In the air pouch-type allergic inflammation model
in rats, total number of leukocytes in the pouch fluid
increased time-dependently after antigen challenge.
In the immunized rats, leukocyte infiltration into the
pouch fluid increased time-dependently, and the num-
ber of infiltrating leukocytes in the pouch fluid at 4
 .and 8 h was significantly P-0.001 higher than
 .that in the non-immunized rats data not shown .
To estimate participation of MIP-2 in the neu-
trophil chemotactic activity in the pouch fluid of the
immunized rats, the effects of varying concentrations
of anti-MIP-2 antibody on the neutrophil chemotactic
activity of the pouch fluid at 8 h were determined. As
shown in Fig. 5, the neutrophil chemotactic activity
in the pouch fluid was inhibited by anti-MIP-2 anti-
body in a concentration-dependent manner. The neu-
trophil chemotactic activity was decreased to almost
the same level as that in non-immunized rats by
 .anti-MIP-2 antibody at 100 mgrml Fig. 5 .
3.4. Production of MIP-2 by infiltrated leukocytes
The leukocytes which had infiltrated into the pouch
fluid collected 4 h after antigen injection were cul-
Fig. 5. Effects of anti-MIP-2 antibody on the chemotactic activity
in the pouch fluid. Pouch fluid was collected from six immunized
rats 8 h after injection of the antigen solution, and diluted to
 .8-fold in RPMI 1640 medium containing 0.25% wrv BSA.
Anti-MIP-2 antibody was added at the indicated concentrations,
and preincubated at 378C for 30 min. The remaining chemotactic
activity in the pouch fluid was determined using modified Boy-
den chambers. Values are the means"SEM from 6 rats. Statisti-
cal significance: ))) P -0.001 vs. pouch fluid without anti-
MIP-2 antibody.
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tured, and neutrophil chemotactic activity in the con-
ditioned medium was determined. Neutrophils ac-
counted for more than 85% of the infiltrating leuko-
cytes in both immunized rats and non-immunized
rats. Neutrophil chemotactic activity in the condi-
tioned medium increased time-dependently, and that
at 4 h in the conditioned medium of the leukocytes
from the immunized rats was higher than that from
the non-immunized rats, and was reduced by anti-
MIP-2 antibody in a concentration-dependent manner
 .Fig. 6 . These findings suggest that the leukocytes
infiltrating into the pouch fluid of the immunized rats
produce MIP-2 when cultured.
3.5. Effects of anti-MIP-2 antibody on neutrophil
infiltration into the pouch fluid of immunized rats
 .Anti-MIP-2 antibody 1.6 mgrpouch was injected
into the air pouch of the immunized rats 6 h after
antigen challenge, and the number of neutrophils in
the pouch fluid at 8 h was determined. As shown in
Fig. 7, the number of neutrophils in the pouch fluid at
8 h was significantly higher than that at 6 h, and
Fig. 6. Effects of anti-MIP-2 antibody on the chemotactic activity
in the conditioned medium of infiltrating leukocytes. Leukocytes
 7 .  .4=10 cells in the pouch fluid from immunized hatched bars
 .and non-immunized rats open bar were incubated for 4 h at
 .378C in 4 ml of RPMI 1640 medium containing 0.25% wrv
BSA, and the conditioned medium was diluted to 10-fold in
medium. Anti-MIP-2 antibody was added at the indicated concen-
trations, and preincubated at 378C for 30 min. The remaining
chemotactic activity was determined using modified Boyden
chambers. Values are the means"SEM of 4 determinations.
Statistical significance: )) P -0.05, ))) P -0.001 vs. corre-
sponding immunized control.
Fig. 7. Effects of anti-MIP-2 antibody on the leukocyte infiltra-
 .tion in allergic inflammation. Anti-MIP-2 antibody 1.6 mg or
 .non-immunized rabbit IgG 1.6 mg was injected into the air
pouch of the immunized rats 6 h after antigen challenge. The
total numbers of leukocytes which had infiltrated into the pouch
fluid were measured 6 and 8 h after injection of the antigen
solution. After differential counting, total numbers of neutrophils
were calculated. Values are the means"SEM from 6 rats. Statis-
tical significance: ))) P -0.01 vs. immunized control at 8 h
with or without control IgG.
injection of anti-MIP-2 antibody at 6 h inhibited
neutrophil accumulation during the following 2 h.
There was no significant difference in the number of
leukocytes between the groups at 6 h and at 8 h
received anti-MIP-2 antibody at 6 h. Injection of IgG
from non-immunized rabbits had no significant effect
 .on leukocyte infiltration Fig. 7 .
4. Discussion
In a series of experiments to clarify the differences
between allergic and non-allergic inflammation using
wan air pouch-type inflammation model in rats 4,19–
x25 , we found that infiltrating leukocytes collected
from sites of allergic inflammation produce signifi-
cantly higher levels of chemotactic factors than those
w xfrom non-allergic sites 11,12 . The major chemotac-
tic factor named LDNCF-2 appears to be identical to
w xrat MIP-2 10 . In the present study, we demonstrated
using a polyclonal antibody to rat MIP-2 that MIP-2
is the major chemoattractant responsible for neu-
trophil infiltration in the late phase of allergic inflam-
mation.
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Expression of rat MIP-2 as a fusion protein with
GST enabled us to purify it in its soluble form
without denaturation. The observation that GST-MIP-
2 showed no chemotactic activity suggested that the
conformation of the N-terminal amino acid region of
MIP-2 is important for binding to its receptor and
transmission of signals, as also reported for IL-8
w x26–28 . GST-MIP-2 expressed in E. coli was di-
gested with thrombin, yielding GlySer-MIP-2 by re-
moving the GST portion. As expected, GlySer-MIP-2
showed similar chemotactic activity to MIP-2 Fig.
.2 .
Anti-MIP-2 antibody strongly suppressed the
 .chemotactic activity of GlySer-MIP-2 Fig. 3 . Al-
though MIP-2 is known to be 67% homologous to
w xCINC-1 8 , anti-MIP-2 antibody had no effect on the
 .chemotactic activity of CINC-1 Fig. 4 . In the pre-
sent study, we found that the chemotactic activity in
the pouch fluid at 2 h was not inhibited by anti-MIP-2
 .antibody data not shown and that at 4 h was slightly
 .inhibited data not shown , but that at 8 h was
 .markedly suppressed Fig. 5 . These findings suggest
that MIP-2 makes a large contribution to the chemo-
tactic activity in the late phase but not in the early
phase of allergic inflammation. Anti-MIP-2 antibody
did not completely abolish the chemotactic activity in
the pouch fluid, but participation of CINC-1 in the
chemotactic activity of the pouch fluid at 8 h was
excluded because its concentration as determined by
w xELISA was very low 10 . Therefore, other
chemokines such as LDNCF-1 or CINC-2, or lipid
chemoattractants might be involved as minor
chemoattractants. The contribution of MIP-2 to neu-
trophil infiltration in the late phase of allergic inflam-
mation was also confirmed by the observation that
injection of anti-MIP-2 antibody into the air pouch 6
h after antigen challenge suppressed neutrophil infil-
 .tration during the next 2-h Fig. 7 . Consistent with
the observation that anti-MIP-2 antibody did not in-
hibit the chemotactic activity in the pouch fluid col-
lected 2 h after antigen challenge, injection of anti-
MIP-2 antibody at the time of antigen challenge did
not inhibit neutrophil infiltration during the following
 .2-h data not shown . This finding also suggested that
MIP-2 plays a significant role in neutrophil infiltra-
tion in the late phase of allergic inflammation.
Chemotactic factors such as C5a, PAF and LTB ,4
and proinflammatory cytokines such as IL-1, tumor
 .necrosis factor a TNFa and IL-8 have been re-
ported to mediate neutrophil accumulation at inflam-
w xmation sites 2–4,23,29–31 . Previously, we demon-
strated that the chemoattractants responsible for neu-
trophil infiltration into the sites of allergic inflamma-
tion differ in the stages after the induction of inflam-
w xmation 24,25 . The major chemoattractants in the
pouch fluid at 2 to 4 h after antigen challenge have
been characterized to be lipophilic. One candidate for
such a lipophilic chemoattractant is PAF, because
injection of PAF antagonists into the pouch at 4 h
w xsuppressed leukocyte infiltration at 8 h 4 . In con-
trast, the major chemotactic factor in the late phase
appears to be MIP-2. It is possible that MIP-2 is
produced by the infiltrating leukocytes in vivo, be-
cause the infiltrating leukocytes in the pouch fluid at
w x4 h express MIP-2 mRNA 10 , and a large propor-
tion of chemotactic activity in the conditioned medium
of the leukocytes was inhibited by anti-MIP-2 anti-
 .body Fig. 6 . The infiltrating leukocytes might pro-
duce MIP-2 and thus recruit neutrophils into inflam-
matory loci in the late phase.
It has been reported that IL-1b and TNFa induce
w xproduction of IL-8, CINC and MIP-2 32–35 . When
IL-1b was injected intratracheally in rats, a marked
increase in the level of MIP-2 mRNA was observed
at 4 h in bronchoalveolar lavage cells and lung
w xtissues 36 . In the air pouch-type allergic inflamma-
tion model, IL-1 activity in the pouch fluid increases
ww xfrom 2 to 4 h after antigen challenge 37 and our
xunpublished observations . These findings suggest the
existence of a cytokine network between proinflam-
matory cytokines and chemokines in the allergic in-
flammation.
In this study, MIP-2 has been demonstrated to be a
major chemoattractant contributing to neutrophil in-
filtration in the allergic inflammation in rats. In hu-
mans, two C-X-C chemokines which share high ho-
mology with murine MIP-2 were cloned from a
cDNA library constructed from PMA- and LPS-
stimulated human monocytic cell line U 937 using a
w xprobe for murine MIP-2 38 . The two human homo-
logues of murine MIP-2 were named human MIP-2a
 .  .Gro-b and MIP-2b Gro-g sharing 57.9% and
59.8% homology with murine MIP-2, respectively
w x38 . However, in humans, IL-8 is a major neutrophil
chemoattractant, playing an important role in inflam-
w xmatory diseases 39–43 . A rat equivalent of human
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IL-8 has not yet been identified. In the conditioned
medium of the granulation tissue obtained from car-
rageenin-induced inflammation in rats, four types of
CINC including CINC-1, -2a , -2b , and -3 also
. w xcalled rat MIP-2 were isolated 8 , suggesting that
they play important roles in the recruitment of neu-
trophils to inflammatory loci. In the exudate of LPS-
induced inflammation in rats, almost equal amounts
w xof CINC-1 and -2 have been detected 44 . However,
the present study demonstrated that rat MIP-2 is a
major chemoattractant in the allergic inflammation.
Therefore, it seems likely that types of chemokine
produced in the inflammatory loci differ depending
on the difference of inflammation.
In conclusion, using polyclonal anti-MIP-2 anti-
body, we demonstrated that MIP-2 is a major chemo-
attractant and plays an important role in the recruit-
ment of neutrophils in the late phase of air pouch-type
allergic inflammation in rats.
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